Lynparza (olaparib) has been recommended for approval in the European Union to treat men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA1 and BRCA2, two DNA repair genes. The marketing authorization application is specific for men whose disease progressed after treatment that included a newer hormone therapy, such as Xtandi (enzalutamide) or Zytiga (abiraterone acetate). The positive opinion by the Committee for Medicinal Products for Human Use (CHMP) was based on a subgroup analysis of mCRPC patients with BRCA mutations from the…
You must be logged in to read/download the full post.
The post Lynparza’s Approval Favored in EU for mCRPC Patients with BRCA Mutations appeared first on BioNewsFeeds.